Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis

References

• Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631–644.
   PubMed Web of Science ®Google Scholar
• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–137.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1–161.e11.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
   PubMed Web of Science ®Google Scholar
• Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth 2009;9:8.
   PubMed Web of Science ®Google Scholar
• Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004;103:981–991.
   PubMed Web of Science ®Google Scholar
• Sep S, Verbeek J, Koek G, Smits L, Spaanderman M, Peeters L. Clinical differences between early-onset HELLP syndrome and early-onset preeclampsia during pregnancy and at least 6 months postpartum. Am J Obstet Gynecol 2010;202:271.e1–271.e5.
   Web of Science ®Google Scholar
• Várkonyi T, Nagy B, Füle T, Tarca AL, Karászi K, Schönléber J, Hupuczi P, et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta 2011;32 Suppl:S21–S29.
   PubMed Web of Science ®Google Scholar
• Heitner JC, Koy C, Kreutzer M, Gerber B, Reimer T, Glocker MO. Differentiation of HELLP patients from healthy pregnant women by proteome analysis–on the way towards a clinical marker set. J Chromatogr B Analyt Technol Biomed Life Sci 2006;840:10–19.
   PubMed Web of Science ®Google Scholar
• Koy C, Heitner JC, Woisch R, Kreutzer M, Serrano-Fernandez P, Gohlke R, Reimer T, Glocker MO. Cryodetector mass spectrometry profiling of plasma samples for HELLP diagnosis: an exploratory study. Proteomics 2005;5:3079–3087.
   PubMed Web of Science ®Google Scholar
• Pecks U, Seidenspinner F, Röwer C, Reimer T, Rath W, Glocker MO. Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: a strategy to distinguish patients with preeclampsia from matching control individuals. J Am Soc Mass Spectrom 2010;21:1699–1711.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–658.
   PubMed Web of Science ®Google Scholar
• Lindheimer MD, Umans JG. Explaining and predicting preeclampsia. N Engl J Med 2006;355:1056–1058.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–649.
   PubMed Web of Science ®Google Scholar
• Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, Rana S. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23:366–370.
   PubMed Web of Science ®Google Scholar
• Hertig A, Fort J, Lefevre G, Chabbert-Buffet N, Uzan M, Rondeau E, Rozenberg P. Soluble endoglin in preeclamptic patients with or without HELLP syndrome. Am J Obstet Gynecol 2010;202:594.e1–594.e4.
   Web of Science ®Google Scholar
• Buimer M, Keijser R, Jebbink JM, Wehkamp D, van Kampen AH, Boer K, van der Post JA, Ris-Stalpers C. Seven placental transcripts characterize HELLP-syndrome. Placenta 2008;29:444–453.
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007;197:244.e1–244.e8.
   Web of Science ®Google Scholar
• Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818–824.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454.
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Speroff T, Ganapathi MK, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032–3037.
   PubMed Web of Science ®Google Scholar
• Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996;26:427–435.
   PubMed Web of Science ®Google Scholar
• Kovacevic A, Hammer A, Sundl M, Pfister B, Hrzenjak A, Ray A, Ray BK, et al. Expression of serum amyloid A transcripts in human trophoblast and fetal-derived trophoblast-like choriocarcinoma cells. FEBS Lett 2006;580:161–167.
   PubMed Web of Science ®Google Scholar
• Zhao Y, He X, Shi X, Huang C, Liu J, Zhou S, Heng CK. Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflamm Res 2010;59:323–334.
   PubMed Web of Science ®Google Scholar
• Baumann H, Richards C, Gauldie J. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol 1987;139:4122–4128.
   PubMed Web of Science ®Google Scholar
• Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009;14:187–196.
   PubMed Web of Science ®Google Scholar
• Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sütsch G, et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005;111:1355–1361.
   PubMed Web of Science ®Google Scholar
• Paternoster DM, Fantinato S, Stella A, Nanhornguè KN, Milani M, Plebani M, Nicolini U, Girolami A. C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost 2006;12:330–337.
   PubMed Web of Science ®Google Scholar
• Ertas IE, Kahyaoglu S, Yilmaz B, Ozel M, Sut N, Guven MA, Danisman N. Association of maternal serum high sensitive C-reactive protein level with body mass index and severity of pre-eclampsia at third trimester. J Obstet Gynaecol Res 2010;36:970–977.
   PubMed Web of Science ®Google Scholar